Intelligence Feed event · Equity · 2026-09-21

    Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%

    Question

    Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%

    Direct answer

    Bristol Myers Squibb (BMY) recorded Q2 net revenue of $12.9 billion, supported by 153% earnings per share growth. The company's pipeline transition achieved a critical milestone, with its designated growth portfolio expanding 15% year-over-year to reach approximately 60% of consolidated revenue. The commercial ramp of new oncology and cardiovascular therapies mitigates the anticipated revenue cliff from patent expirations on legacy blockbuster products, driving a 17% year-to-date share appreciation.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/bristol-myers-squibb-posts-12-9b-revenue-as-growth-portfolio-hits-60-8d2212

    EQUITY
    Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%
    Bristol Myers Squibb (BMY) recorded Q2 net revenue of $12.9 billion, supported by 153% earnings per share growth. The company's pipeline transition achieved a critical milestone, with its designated growth portfolio expanding 15% year-over-year to reach approximately 60% of consolidated revenue. The commercial ramp of new oncology and cardiovascular therapies mitigates the anticipated revenue cliff from patent expirations on legacy blockbuster products, driving a 17% year-to-date share appreciation.
    BMY
    Impact
    66
    SEP 21
    SIG
    88%
    BMY
    Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%
    Bristol Myers Squibb (BMY) recorded Q2 net revenue of $12.9 billion, supported by 153% earnings per share growth. The company's pipeline transition achieved a critical milestone, with its designated growth portfolio expanding 15% year-over-year to reach approximately 60% of consolidated revenue. The commercial ramp of new oncology and cardiovascular therapies mitigates the anticipated revenue cliff from patent expirations on legacy blockbuster products, driving a 17% year-to-date share appreciation.
    → Expansion of the 15% YoY growth drug portfolio to 60% of revenue insulates aggregate BMY cash flows against legacy patent expirations.
    Impact
    Bristol Myers Squibb (BMY) recorded Q2 net revenue of $12.9 billion, supported by 153% earnings per share growth. The company's pipeline transition achieved a critical milestone, with its designated growth portfolio expanding 15% year-over-year to reach approximately 60% of consolidated revenue. The commercial ramp of new oncology and cardiovascular therapies mitigates the anticipated revenue cliff from patent expirations on legacy blockbuster products, driving a 17% year-to-date share appreciation.
    Affected
    BMY
    Transmission
    Expansion of the 15% YoY growth drug portfolio to 60% of revenue insulates aggregate BMY cash flows against legacy patent expirations.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYpipeline transition offsetting patent cliff via 15% growth portfolio expansionUp1-4wQ2 revenue reached $12.9B with growth portfolio accounting for ~60% of revenue

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month